Total synthesis of natural derivatives and artificial analogs of 13-oxyingenol and their biological evaluation by Ohyoshi Takayuki et al.
Total synthesis of natural derivatives and
artificial analogs of 13-oxyingenol and their
biological evaluation
著者 Ohyoshi Takayuki, Tamura Yuki, Hayakawa
Ichiro, Hirai Go, Miyazawa Yamato, Funakubo
Shota, Sodeoka Mikiko, Kigoshi Hideo
journal or
publication title
Organic & biomolecular chemistry
volume 14
number 48
page range 11426-11437
year 2016-12
権利 (C) The Royal Society of Chemistry 2016
URL http://hdl.handle.net/2241/00145097
doi: 10.1039/C6OB02268E
Journal Name  
ARTICLE 
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 1  
Please do not adjust margins 
Please do not adjust margins 
a.
 Department of Chemistry, Graduate School of Pure and Applied Sciences, 
University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8571, Japan. E-mail: 
kigoshi@chem.tsukuba.ac.jp 
b.
 Synthetic Organic Chemistry Laboratory, RIKEN, 2-1 Hirosawa, Wako, Saitama 
351-0198, Japan. E-mail: gohirai@riken.jp; sodeoka@riken.jp 
c.
 Division of Applied Chemistry, Graduate School of Natural Science and 
Technology, Okayama University, 3-1-1 Tsushima-naka, Kita-ku, Okayama 700-
8530, Japan. E-mail: ichiro.hayakawa@okayama-u.ac.jp 
d.
 RIKEN Center for Sustainable Resource Science, 2-1 Hirosawa, Wako, Saitama 
351-0198, Japan 
e.
 AMED-CREST, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan 
f.
 Present address: Graduate School of Pharmaceutical Sciences, Kyushu University, 
Maidashi, Higashi-ku, Fukuoka 812-8582, Japan 
† Electronic Supplementary Information (ESI) available: Experimental protocols, 
characterization of data and NMR spectra of all new compounds. See 
DOI: 10.1039/x0xx00000x 
Received 00th January 20xx, 
Accepted 00th January 20xx 
DOI: 10.1039/x0xx00000x 
www.rsc.org/ 
Total synthesis of natural derivative and artificial analogs of 13-
oxyingenol and their biological evaluation 
Takayuki Ohyoshi,
a
 Yuki Tamura,
b
 Ichiro Hayakawa,*
c
 Go Hirai,*
b,d,e,f
 Yamato Miyazawa,
a
 Shota 
Funakubo,
a
 Mikiko Sodeoka*
,b,d,e
 and Hideo Kigoshi*
a 
We have established an efficient synthetic methodology for 13-oxyingenol natural derivative (13-oxyingenol 13-
dodecanoate 20-hexanoate), featuring a ring-closing olefin metathesis reaction for the "direct" construction of a highly 
strained inside–outside framework and a Mislow–Evans-type [2,3]-sigmatropic rearrangement for the stereoselective 
introduction of the hydroxy group at C5. We also synthesized artificial analogs of 13-oxyingenol and ingenol by using our 
synthetic strategy. In vitro activation assays of protein kinase C (PKC) α and δ revealed that the dodecanoyl group at O13 
on 13-oxyingenol analogs had a significant role in PKCδ activation. The PKCα- or PKCδ-activating 13-oxyingenol and ingenol 
analogs induced both distinct morphological changes and increases CD11b expression in HL-60 cells, which would be 
typical signs of HL-60 cell differentiation to macrophage-like cells, as expected by previous reports. Intriguingly, however, 
similar differentiation phenotypes were observed with the use of 13-oxyingenol natural derivatives and 13-oxyingenol 13-
dodecanoate showing a remarkably less potent PKCα or PKCδ activation ability, which PKC inhibitor Gö6983 diminished. 
This indicated the involvement of other PKC isozymes or related kinase activities. 13-Oxyingenol analogs, which induced 
HL-60 cell differentiation, also induced HL-60 cell death, similar to the action of a phorbol ester, a strong PKC activator.
Introduction 
13-oxyingenol 13-dodecanoate 20-hexanoate (13-oxyingenol 
natural derivative; 13-oxyingenol derivative) (1) was isolated 
from Euphorbia kansui plants by Uemura et al. (Figure 1).
1
 The 
structural features of 1 is a high degree of oxygenation and a 
highly strained unique bicyclo[4.4.1]undecane skeleton with 
trans intrabridgehead stereochemistry at the BC rings, which is 
called an inside–outside framework. Ingenol (3) has the same 
framework of 1,
2
 and ingenol 3-angelate (Picato
®
) (4) was 
approved by the FDA as a topical treatment for solar 
keratosis.
3
 In 1996, Fujiwara et al. reported the structure–
activity relationship study of 1.
4
 As a results, a 13-oxyingenol 
analog, RD4-2227 (2), showed a potent inhibitory effect at 
picomolar concentrations on HIV-1 (HTLV-IIIB) replication in 
MT-4 cells (EC50 = 140 pM). This is stronger than the inhibitory 
effect of 3 (5,200,000 pM) or of anti-HIV drug zidovudine 
(Retrovir
®
) (4,100 pM) under the same assay conditions. 
 
 
Fig. 1 Structures of 13-oxyingenols and ingenols. 
 
Ingenol analogs are reported to be involved in the modulation 
of protein kinase C (PKC) enzyme activity.
5
 PKCs are a family of 
serine/threonine kinases and are key mediators of many 
intracellular signal transduction pathways involved in cell 
growth, differentiation, carcinogenesis and cell death.
6
 PKCs 
are categorized into three classes: conventional (cPKCs), novel 
(nPKCs), and atypical (aPKCs). The binding of ligands such as 
endogenous second messenger diacylglycerol (DAG) and 
tumor promoter phorbol esters (e.g., phorbol 12-myristate 13-
acetate; PMA) to the C1 domain in cPKCs and nPKCs, but not in 
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aPKCs, triggered the enhancement of enzymatic activity. The 
crystal structure of the PKCδ C1 domain with phorbol ester 
revealed crucial hydrogen bonding interactions between the 
hydrophilic cleft of the C1 domain and phorbol esters.
7
 Some 
ingenol derivatives, especially those that have an acyl group on 
the hydroxyl group at C3, were reported to be C1 domain 
ligands and to activate PKC, which was explained by their 
structural similarities with phorbol esters. For 13-oxyingenol 
analogs, RD4-2227 (2) was identified as a potent nontoxic PKC 
activator (no toxicity was observed in mice up to 0.1 mg kg
–
1
day
–1
 by intraperitoneal injection).
4a
 Non-tumor-promoting 
PKC activators, such as bryostatin 1,
8
 prostratin,
9
 and 
aplysiatoxin analogs,
10
 have been attracting attention as 
potential therapeutic agents for acquired immune deficiency 
syndrome (AIDS), tumors, and Alzheimer's disease. Thus, the 
activities of 13-oxyingenol analogs, which have an additional 
functionalization site at the C13 position in 13-oxyingenol as 
compared to ingenol analogs, have been of great interest. 
However, the structure‒activity relationships of 13-oxyingenol 
derivatives are still largely unknown, which hampers further 
rational molecular design and obscures the merit of 13-
oxyingenols for use as parent compounds. We anticipated that 
the development of an efficient synthetic methodology for 1 
would enable us to provide a practical synthetic route for 
research supply of its analogs and to conduct further biological 
studies in order to uncover the characteristic features of 1. 
The unique stereostructures of the ingenol family have made 
them attractive targets for total synthesis.
11
 Four groups have 
achieved the total synthesis of ingenol (3): Winkler,
12
 Tanino–
Kuwajima,
13
 Wood,
14
 and Baran
15
. Also, several groups have 
reported the synthesis of the ingenol skeleton.
16
 Whereas 
many groups have constructed the highly strained inside–
outside framework of 3 by using rearrangement or 
fragmentation reactions, we developed a "direct" construction 
method using the ring-closing olefin metathesis (RCM) 
reaction.
17
 We then achieved the formal synthesis of optically 
active 3 using this methodology as a key step.
18
 Wood et al. 
accomplished the total synthesis of ingenol by using similar 
approach in 2004.
14
 We also have investigated the synthesis of 
13-oxyingenol derivative (1).
19
 In 2012, we preliminarily 
reported the total synthesis of 1.
20
 The highlights of this 
approach are the use of an RCM reaction for the direct 
construction of an inside–outside framework and a Mislow–
Evans-type [2,3]-sigmatropic rearrangement
21
 for the 
stereoselective introduction of a hydroxy group at C5. We 
describe herein the history of the total synthesis of 13-
oxyingenol derivative (1). Furthermore, we discuss the 
synthesis and activities against PKC of the C3-acyloxy 13-
oxyingenol and ingenol analogs. 
 
Results and disscussion 
Construction of the A-ring portion of 13-oxyingenol derivative (1) 
The retrosynthetic pathway of 13-oxyingenol derivative (1) is 
shown in Scheme 1. We planned to construct the B-ring 
portion by using ring-opening reaction of the epoxy group in 5. 
To introduce the requisite functional groups at the A-ring 
portion, we decided to use the introduced hydroxy group at C2. 
The secondary hydroxy group at the C5 in the B-ring portion 
would be introduced by using regio- and stereoselective 
epoxidation of allylic alcohol 6 and the subsequent ring-
opening reaction of the epoxy group in 5. Allylic alcohol 6 was 
prepared by regio- and stereoselective dihydroxylation at the 
most strained ∆
3,4
 olefin in triene 7, which might be obtained 
from tetracyclic ketone 8. The inside–outside framework of 8 
was prepared by using an RCM reaction of diene 9. Diene 9 can 
be synthesized from spiro-ketone 10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1 Retrosynthetic pathway of 13-oxyingenol derivative (1). 
 
The synthesis of epoxide 5 started from the spiro-ketone 10, 
which is our previous intermediate (Scheme 2).
19c
 Thus, the 
introduction of an allyl group to the C8 position of spiro-
ketone 10 with iodide 11 gave diene 9. Diene 9 was treated 
with the second-generation Hoveyda–Grubbs (HG-II) catalyst 
(37)
22
 to afford tetracyclic ketone 8, which possessed the 
inside–outside framework. We attempted the stereoselective 
introduction of the functional groups at the A- and B-rings 
from 8. The removal of the MPM group of 8 followed by 
oxidation of the resulting secondary hydroxy group with Dess–
Martin periodinane
23
 gave diketone 12. We next tried to 
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synthesize enone 13 from 12. Regioselective deprotonation at 
the H3 in 12 and silylation of the resultant enolate with TMSCl 
gave an enol silyl ether as the sole product, which was oxidized 
by using Ito–Saegusa oxidation
24
 to afford 13 (95% yield in two 
steps). In this deprotonation of 12, deprotonation at the H1 
did not proceed, presumably due to the steric hindrance of the 
methyl group at the C18. Enone 13 was converted into an enol 
triflate, which was subjected to the Negishi coupling
25
 reaction 
with Me2Zn to afford triene 7. Regio- and stereoselective 
dihydroxylation of 7 with a stoichiometric amount of OsO4 
gave diol 14. The high regio- and stereoselectivity could be 
explained by the shielding of the ∆
1,2
 olefin by the steric 
hindrance of the C18 methyl group and by the enhancement of 
the reactivity by the pyramidal distortion of ∆
3,4
 olefin. We 
succeeded in synthesizing the A-ring portion of 13-oxyingenol 
derivative (1) by using the C2 hydroxy group. Next, we 
attempted to functionalize the B-ring portion of 1. Protection 
of the secondary hydroxy group of 14 with a benzoyl group 
gave allylic alcohol 6, which was converted into epoxide 5 as a 
single isomer. In this epoxidation, stereoselectivity was 
controlled by the tertiary hydroxy group at the C4 and the cage 
structure of 6. The stereochemistry of 5 was established by X-
ray crystallographic analysis of crystalline p-bromobenzoate 15 
(Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2 Synthesis of epoxide 5. Reagents and conditions: (a) 11, LDA, THF, 
HMPA, –10 °C, 90%; (b) HG-II (37), toluene, reflux, 98%; (c) DDQ, tBuOH, 
phosphate buffer (pH = 6.6), CH2Cl2, rt, 61%; (d) Dess–Martin periodinane, CH2Cl2, 
rt, 87%; (e) TMSCl, LHMDS, Et3N, THF, –78 °C; (f) Pd(OAc)2, MeCN, rt, 95% in two 
steps; (g) Tf2NPh, LHMDS, THF, 0 °C; (h) Pd(PPh3)4, Me2Zn, THF, rt, quant in two 
steps; (i) OsO4, py, THF, 0 °C, then NaHSO3 aq, rt, 99%; (j) BzCl, Et3N, DMAP, 
CH2Cl2, 0 °C, 94%; (k) 
tBuOOH, VO(acac)2, benzene, rt, quant; (l) K2CO3, MeOH, rt; 
(m) p-BrBzCl, Et3N, DMAP, CH2Cl2, 83% in two steps. TBS =  tert-butyldimethylsilyl, 
LDA = lithium diisopropylamide, THF = tetrahydrofuran, HMPA = 
hexamethylphosphoramide, DDQ = 2,3-dichloro-5,6-dicyano-1,4-benzoquinone, 
TMS = trimethylsilyl, Ac = acetyl, Ph = phenyl, LHMDS = lithium 
bis(trimethylsilyl)amide, Tf = trifluoromethanesulfonyl, DMAP = N,N-
dimethylaminopyridine, Bz = benzoyl, acac = acetylacetonyl.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 X-ray crystallographic structure of 15 (CCDC 1508569) 
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With a fully substituted tetracyclic compound 5 in hand, we 
next tried the ring-opening reaction of the epoxy group in 5 
(Table 1). In entries 1 and 2, the ring-opening reaction of the 
epoxy group was investigated by using TfOH as a Brønsted acid 
or Al(O
i
Pr)3 as a Lewis acid.
26
 However, the desired compound 
16 was not obtained. Next, the ring-opening reaction was 
examined by using TMSOTf and DBU (entry 3).
27 
Again, 
however, the reaction did not give 16, but rather undesired 
compounds 17 and 18. The production of these undesired 
compounds can be explained as follows (Scheme 3). First, the 
carbonyl group at the C9 in 5 was activated by TMSOTf as 20, 
and allylic cations 21 and 22 were generated by the migration 
of blue or green bonds, respectively. The methyl proton at the 
C19 in the resulting cations 21 and 22 were removed by DBU 
to give compounds 17 and 18, respectively. Because the 
desired epoxide-opening reaction under acidic conditions did 
not afford 16, we next investigated the reaction under basic 
conditions (entries 4 and 5). The ring-opening reaction of 5 
with LDA was attempted, but 16 was not obtained (entry 4). 
This reaction afforded a complex mixture containing 
byproducts, such as those that seemed to form via the allylic 
anion at the C19 in 5. In entry 5, the treatment of 5 by an 
aluminum amide
28
 did not give the desired ring-opening 
compound 16. We next attempted the ring-opening reaction 
under radical conditions (entry 6). Treatment of 5 with 
Cp2TiCl
29
 gave only the undesired compound 19 and not the 
desired 16. A plausible reaction pathway for the formation of 
19 is shown in Scheme 4. The generated tertiary radical at the 
C6 in 23 attacked to the carbonyl group to give oxy-radical 24. 
The fragmentation of 24 and the subsequent ring-opening 
reaction of the cyclopropane ring formed compound 19. The 
structure of 19 was determined by X-ray crystallographic 
analysis.
30
 Despite these attempts, we could not establish 
reaction conditions for the ring-opening reaction of the epoxy 
group in 5. Therefore, we reexamined the strategy of 
constructing the A- and B-ring portions of 13-oxyingenol 
derivative (1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 Ring-opening reaction of epoxide 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DBU = 1,8-diazabicyclo[5.4.0]undec-7-ene, Cp = cyclopentadienyl. 
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Scheme 3 Proposed reaction mechanism for the formation of compounds 17 and 
18. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 4 Proposed reaction mechanism of formation of compound 19. 
 
Construction of the B-ring portion of 13-oxyingenol derivative (1) 
The modified retrosynthetic pathway of 13-oxyingenol 
derivative (1) is shown in Scheme 5. As mentioned above, we 
established the functionalization of the A-ring portion. In this 
section, we mainly describe the construction of the B-ring 
portion of 1. We planned to introduce the ∆
6,7
 olefin and chiral 
secondary hydroxy group at the C5 in the B-ring portion by 
using Mislow–Evans-type [2,3]-sigmatropic rearrangement.
21,31
 
This strategy has the benefit of constructing the ∆
6,7
 olefin and 
the C5 stereocenter at once. This precursor 27 might be 
obtained from alcohol 28 by SN2 reaction with a selenide anion 
at the C7. Alcohol 28 was synthesized by an aldol reaction 
between 10 and the unsaturated aldehyde 30 for the 
introduction of the hydroxy group at the C7 and the ring-
closing olefin metathesis reaction of the resultant 29. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 5 Modified retrosynthetic pathway of 13-oxyingenol derivative (1). 
 
We prepared precursors for the RCM reaction, such as 29, 
from spiro-ketone 10 (Scheme 6). The aldol reaction between 
10 and unsaturated aldehyde 30
32
 gave allylic alcohol 29 as a 
single diastereomer. The stereochemistry of C7 in 29 was 
determined after the RCM reaction. Aldol 29 was converted 
into acetate 31, TMS ether 32, and unsaturated ketone 33 as 
the precursors for the RCM reaction. 
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Scheme 6 Syntheses of precursors for the RCM reaction. Reagents and 
conditions: (a) 30, NaHMDS, THF, –78 °C; (b) Ac2O, DMAP, py, 50 °C, 83% in two 
steps for 31; (c) TMSCl, imidazole, DMF, rt, 47% in two steps for 32; (d) Dess–
Martin periodinane, CH2Cl2, rt, 81% in two steps for 33. MPM = p-methoxybenzyl, 
NaHMDS = sodium bis(trimethylsilyl)amide, DMF = N,N-dimethylformamide. 
 
Next, the RCM reactions of the precursors were optimized 
(Table 2). We examined the RCM reactions of precursors 29 
and 31–33 with HG-II catalyst (37).
22
 First, the RCM reaction of 
allylic alcohol 29 was attempted, but the yield was moderate 
(54%) (entry 1). Because this reaction gave spiro-ketone 10, we 
supposed that a retro-aldol reaction occurred under this RCM 
condition. We next investigated the RCM reactions with 
acetate 31 and the TMS ether 32. However, the yields were 
still moderate (entry 2: 64%, entry 3: 49%). These results 
indicated that the RCM reaction was most efficiently effected 
by using 31. Therefore, we next screened solvents by using 31 
as a precursor. In entry 4, we attempted the RCM reaction in 
boiling benzene, but the yield was low. Halogenated aromatic 
solvents, such as 1,2-dichlorobenzene (reaction at 120 °C) and 
trifluorobenzene (reaction at reflux) (entries 5 and 6) did not 
improve the yields. We also screened an assortment of Ru 
catalysts. The RCM reaction with highly active Ru catalyst 38
33
 
afforded tetracyclic ketone 34 in 51% yield (entry 7), whereas 
the RCM reaction with the less-hindered Ru catalyst (Stewart–
Grubbs catalyst) 39
34
 did not yield the desired compound 34 
(entry 8). These results indicated that the use of acetate 31 
cannot improve the yield of the RCM reaction. Next, we tried 
the RCM reaction with α,β-unsaturated ketone 33 as a 
precursor, because the steric hindrance around the C7 of the 
α,β-unsaturated ketone group at C7 is smaller in 33 than in 
acetate 31 and because the reactivity of the enone is suitable 
for the RCM reaction. The reaction of α,β-unsaturated ketone 
33 with HG-II catalyst (37) in boiling toluene proceeded 
smoothly to afford the desired tetracyclic ketone 36 in 86% 
yield (entry 9). On the basis of these results, we established an 
optimized precursor and reaction conditions for the RCM 
reaction. 
 
Table 2 Optimization of RCM reaction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mes = mesityl, Tol = p-tolyl. 
 
With tetracyclic ketone 36, which has an oxygen functional 
group at the C7, in hand, we examined the construction of the 
B-ring portion. Reduction of the carbonyl group at the C7 in 36 
proceeded from the convex face in a highly stereoselective 
manner to give allylic alcohol 28 (Scheme 7). Mesylation of the 
resultant hydroxy group of 28 by the Tanabe method
35
 
afforded mesylate 40, and the introduction of a phenylselenyl 
group by the selenide anion prepared from (PhSe)2 and NaBH4 
gave selenide 41. Oxidation of 41 by m-CPBA gave a selenoxide, 
which was treated with P(OMe)3 to afford [2,3]-sigmatropic 
rearrangement product 26. Thus, we established the 
construction of the B-ring portion by using [2,3]-sigmatropic 
rearrangement as a key step. 
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Scheme 7 Synthesis of allylic alcohol 26. Reagents and conditions: (a) DIBAL, 
toluene, –78 °C, 96%; (b) MsCl, Me2N(CH2)3NMe2, toluene, 0 °C; (c) (PhSe)2, 
NaBH4, THF, EtOH, rt, 96% in two steps; (d) m-CPBA, THF,  –78 °C; (e) P(OMe)3, 
MeOH, 0 °C, 76% in two steps. Ms = methanesulfonyl, m-CPBA = m- 
chloroperbenzoic acid. 
 
Next, we tried to construct the A-ring portion of 13-oxyingenol 
derivative (1) using a similar strategy as that shown in Scheme 
2. Removal of two MPM groups in 26 afforded triol 42 (Scheme 
8). The 1,3-diol group in 42 was protected as an acetonide, and 
the remaining secondary hydroxy group at the C2 was oxidized 
by Dess–Martin periodinane to give diketone 43.
36
 We next 
attempted the Ito–Saegusa oxidation of 43. However, we did 
not obtain the desired enone 44, but rather an undesired 
compound 45. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 8 Attempt to functionalize the A-ring portion. Reagents and conditions: 
(a) DDQ, tBuOH, phosphate buffer (pH = 6.6), CH2Cl2, rt, 52%; (b) 2-
methoxypropene, PPTS, benzene, rt; (c) Dess–Martin periodinane, PPTS, CH2Cl2, 
rt, 90% in two steps; (d) TMSCl, LHMDS, Et3N, THF, –78 °C; (e) Pd(OAc)2, MeCN, rt. 
PPTS = pyridinium p-toluenesulfonate.  
 
We can interpret the mechanism underlying the undesired 
reaction in the following way (Scheme 9): deprotonation of H3 
in diketone 43 gave anion 46, the fragmentation of which 
afforded enolate 47. Enolate 47 was then transformed into 
dienolate 48, which was converted into 45 by an electrocyclic 
reaction. We thought that this undesired reaction was due to 
the highly strained pentacyclic skeleton of 43. Therefore, we 
tried to convert the acetonide group into another protecting 
group to decrease the strain. 
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Scheme 9 Proposed reaction mechanism of formation of compound 45. 
 
Protection of the secondary hydroxy group in 26 with a TES 
group and removal of two MPM groups afforded diol 49 
(Scheme 10). The primary alcohol in 49 was protected as a TBS 
group, and the remaining secondary hydroxy group at the C2 
was oxidized by Dess–Martin periodinane to give diketone 50. 
Diketone 50 was oxidized to enone 51 by using Ito–Saegusa 
oxidation. In this case, a rearrangement compound, such as 
compound 45, was not afforded. Enone 51 was converted into 
an enol triflate, which was transformed into triene 52 by using 
Negishi coupling. Next, the regio- and stereoselective 
dihydroxylation of 52 with a stoichiometric amount of OsO4 
was carried out. However, the desired diol 53 was not 
obtained, but rather the undesired compound 54, which was 
oxidized at the ∆
6,7
 olefin, was obtained. We thought that 
steric hindrance of the TES group in 52 interfered with the 
electrophilic attack of OsO4 at the ∆
3,4
 olefin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 10 Study of functionalization of the A-ring portion. Reagents and 
conditions: (a) TESOTf, 2,6-lutidine, CH2Cl2, 0 °C, 89%; (b) DDQ, 
tBuOH, phosphate 
buffer (pH = 6.6), CH2Cl2, rt, 84%; (c) TBSCl, Et3N, DMAP, CH2Cl2, rt, quant; (d) 
Dess–Martin periodinane, CH2Cl2, rt, 91%; (e) TMSCl, LHMDS, Et3N, THF, –78 °C; 
(f) Pd(OAc)2, MeCN, rt, 50% in two steps; (g) Tf2NPh, LHMDS, THF, 0 °C; (h) 
Pd(PPh3)4, Me2Zn, THF, rt, 77% in two steps; (i) OsO4, THF, py, 0 °C then NaHSO3, 
rt. TES = triethylsilyl, py = pyridine. 
 
We found it difficult to introduce functional groups at the A-
ring portion after the construction of the B-ring portion. Thus, 
we next tried to construct the A-ring portion before 
constructing the B-ring portion. Removal of two MPM groups 
in 34 and subsequent hydrolysis of the acetyl group gave a triol, 
which was converted into acetonide 55 (Scheme 11). 
Acetonide 55 was transformed into diol 56 by using our 
established synthetic strategy (Scheme 2). Protection of the 
diol group in 56 with a cyclic carbonate group and removal of 
the TBS group gave a diol, which was transformed into alcohol 
57 by selective silylation of the primary hydroxy group. We 
next examined the introduction of a phenylselenyl group at 
the C7 in 57. The mesylation of 57 afforded mesylate 58, which 
was treated with (PhSe)2 and NaBH4. However, selenide 59 
was not obtained. This suggested that steric hindrance of the 
cyclic carbonate group in 58 interfered with the nucleophilic 
attack by a selenide anion. 
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Scheme 11 Attempt to functionalize the B-ring portion. Reagents and conditions: 
(a) DDQ, tBuOH, phosphate buffer (pH = 6.6), CH2Cl2, rt; (b) 1 M LiOH aq, THF, 
MeOH, rt; (c) 2-methoxypropene, PPTS, benzene, rt, 87% in three steps; (d) 
carbonyl diimidazole, benzene, rt; (e) PPTS, EtOH, 50 °C; (f) TBSCl, Et3N, DMAP, 
CH2Cl2, rt, 60% in three steps; (g) MsCl, Me2N(CH2)3NMe2, toluene, 0 °C; (h) 
(PhSe)2, NaBH4, THF, EtOH, rt to reflux. 
 
Total synthesis of 13-oxyingenol derivative (1) 
As described above, we constructed each of the A- and B-ring 
portions of 13-oxyingenol. However, we were unable to 
construct both of A- and B-rings in a molecule (Schemes 8 and 
10). Therefore, we attempted to construct the A-ring portion 
at the next stage of the introduction of an aromatic selenyl 
group at the C7 (Scheme 12). Two MPM groups in selenide 41 
were removed by using DDQ to afford diol 60. Selective 
protection of the primary hydroxy group of 60 with a TBS 
group and the remaining secondary hydroxy group at the C2 
was oxidized by Parikh–Doering oxidation
37
 to give diketone 62. 
Other oxidation conditions, such as Dess–Martin oxidation and 
Ley–Griffith oxidation,
38
 gave Mislow–Evans-type 
rearrangement byproducts along with desired 62. Diketone 62 
was oxidized into enone 63 by using Ito–Saegusa oxidation. 
Enone 63 was treated with LHMDS and Tf2NPh to form an enol 
triflate, which was subjected to Negishi coupling to afford 
triene 64. Regio- and stereoselective dihydroxylation of the 
∆
3,4
 olefin in triene 64 with a stoichiometric a mount of OsO4 
gave the desired diol 65. During conversion of selenide 41 into 
65, the phenylselenyl group was not affected by oxidizing 
agents, such as DDQ, SO3·py–DMSO, and OsO4. We next 
examined the introduction of the C5 hydroxy group by using a 
Mislow–Evans-type rearrangement. The oxidation of the 
aromatic selenide group in 65 using m-CPBA and subsequent 
[2,3]-sigmatropic rearrangement with P(OMe)3 afforded triol 
66. Thus, both the A- and B-ring portions of 13-oxyingenol 
derivative (1) were successfully constructed. The removal of 
two TBS groups in 66 afforded 13-oxyingenol (67), and four 
hydroxy groups at the A- and B-ring portions of 67 were 
protected as two acetonide groups to afford compound 68. 
The introduction of the dodecanoyl ester group at the 
remaining tertiary hydroxy group at C13 in 68 gave 69, which 
was hydrolyzed into 13-oxyingenol 13-dodecanoate (70). 
Finally, selective acylation of the primary hydroxy group in 
tetraol 70 formed 13-oxyingenol derivative (1). The spectral 
data (
1
H NMR and 
13
C NMR spectroscopy, HRMS, and optical 
rotation) of synthetic 1 were in full agreement with those of 
the natural product, thus completing the total synthesis (1.4% 
overall yield in 41 steps).  
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Scheme 12 Total synthesis of 13-oxyingenol derivative (1). Reagents and conditions: (a) DDQ, tBuOH, phosphate buffer (pH = 6.6), CH2Cl2, rt, quant; (b) TBSCl, Et3N, 
DMAP, CH2Cl2, rt, 97%; (c) SO3∙py, DMSO, Et3N, CH2Cl2, rt, quant; (d) TMSCl, LHMDS, Et3N, THF, –78 °C; (e) Pd(OAc)2, DMSO, rt, 64% in two steps; (f) Tf2NPh, LHMDS, 
THF, –40 °C; (g) Pd(PPh3)4, Me2Zn, THF, rt; (h) OsO4, py, THF, then NaHSO3, rt, 64% in three steps; (i) m-CPBA, THF,  –78 °C; (j) P(OMe)3, MeOH, 0 °C, 61% in two steps; 
(k) HF∙py, THF, py, rt, quant; (l) 2,2-dimethoxypropane, PPTS, CH2Cl2, rt; (m) C11H23CO2H, EDCl, DMAP, CH2Cl2, rt, 63% in two steps; (n) 1 M HCl, THF, rt, 99%; (o) 
(C5H11CO)2O, Et3N, CH2Cl2, –20 °C, 85%. DMSO = dimethylsulfoxide, EDCl = 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride. 
 
Synthesis of artificial analogs of the 13-oxyingenols and ingenols 
To investigate the structure–activity relationship of 13-
oxyingenol derivative (1), we prepared artificial analogs of 13-
oxyingenol. Because RD4-2227 (2) and ingenol 3-angelate (4) 
show potent biological activity, we focused on the C3-acyloxy 
13-oxyingenol analogs. We synthesized the C3-acyloxy analogs 
from our synthetic intermediate 70 (Scheme 13). Selective 
protection of the 1,3-diol group at C5 and C20 with an 
acetonide group gave mono acetonide 71.
39
 Selective acylation 
of the O3-hydroxy group and removal of the acetonide group 
afforded various C3-acyloxy 13-oxyingenol analogs, pivalate 2 
(RD4-2227), angelate 76, tetradecanoate 77, and benzoate 78. 
On the other hand, to examine the effect of the dodecanoyl 
ester group at the C13 in 13-oxyingenol analogs, C3-acyloxy 
ingenol analogs 4 and 84–86 were also prepared from ingenol 
(3)
40
 by using the same strategy for the C3-acyloxy 13-
oxyingenol analogs. 
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Scheme 13 Syntheses of the artificial analogs of 13-oxyingenol and ingenol. 
Reagents and conditions: (a) p-TsOH∙H2O, acetone, rt, 50% for 71, 57% for 79; (b) 
(RCO)2O, Cs2CO3, MeCN, rt, for 72–74, 80–82; (c) BzCl, Et3N, DMAP, CH2Cl2, rt, for 
75 and 83; (d) 0.5% HCl aq, MeOH, rt. Ts = p-toluenesulfonyl. 
 
PKCα and PKCδ activation abilities of 13-oxyingenol natural 
derivative (1) and its artificial analogs 
The enhancement of PKC activity by 13-oxyingenol and ingenol 
analogs was evaluated in vitro for PKCα (as a representative of 
cPKCs) and PKCδ (as a representative of nPKCs). First, the 
effects of the compounds (10 nM for PKCα and 100 nM for 
PKCδ) on the enzyme activities were examined. As shown in 
Table 3, analogs without the acyl group on the O3 position (R
2
 
= H) did not show significant activation of either PKCα or PKCδ, 
indicating that the 3-acyloxy group is essential for PKC 
activation as suggested previously.
4a,15c
 Other derivatives 
showed the dose-dependent activation of PKCα and PKCδ 
(Figures S2 and S4). Regardless of the presence or absence of 
the 13-acyloxy group (R
1
), a similar activation level of PKCα 
was observed for ingenol analogs (4, 84–86) and 13-oxyingenol 
analogs (2, 76–78). In contrast, it should be noted that PKCδ 
activity was clearly susceptible to the 13-acyloxy group. 
Though compounds 2, 76, and 78 exhibited remarkable 
activation of PKCδ, the corresponding ingenol analogs (4, 84, 
and 86) showed much lower activation. The bulkiness of the 3-
acyl group (R
2
) also seemed to affect PKCα activation ability, as 
we observed in our isobenzofuranone ligands before.
41
 The 
branched pivaloyl derivatives (2 and 84) showed stronger 
activation than the straight chain myristoyl analogs (77 and 85). 
These results indicated that 13-oxyingenol analogs with a long 
acyl chain at the C13 position and a short bulky acyl group at 
the C3 position have the potential for broad activation ability 
toward both cPKCs and nPKCs. On the other hand, the 
activation abilities of compound 77 having two long straight 
acyl chains similar to DAGs were low, and indeed were lower 
than those of compound 85, which lacks a long acyl chain at 
C13.  
 
HL-60 cell differentiation and cell death 
We further examined the biological effects of 13-oxyingenol 
analogs at the cellular level. It has been reported that ingenol 
3-angelate (4) induced the differentiation and apoptosis of HL-
60 cells, and that PKCδ would play a critical role in these 
effects.
42
 Since CD11b was reported as an early marker of HL-
60 cell differentiation, the expression levels of CD11b of HL60 
cells treated with PMA and the ingenol and 13-oxyingenol 
analogs (1 μM, 24 hr) were measured by flow cytometry. The 
relative expression levels (%) compared to PMA are shown in 
Table 3. CD11b expression was greatly induced by all of the 
compounds except compounds 67 and 3 (see also Figure S6). 
Furthermore, morphological changes in HL-60 cells, cell 
aggregation, cell attachment and pseudopodia formation, 
induced by these ingenol and 13-oxyingenol analogs were 
confirmed by microscopic observations (Figure 3 and Figure 
S5).  
In addition, the induction of apoptosis by the treatment of 
these compounds (1 μM, 48 hr) was also quantified by 
measuring the sub-G1 population by flow cytometry. Similar to 
ingenol 3-angelate (4), these compounds induced apoptosis 
(Table 3 and S7).  
Compounds 67 and 3, each lacking the ability to active PKCα 
and δ, did not induce morphological changes, expression of 
CD11b, or the death of HL-60 cells. These results suggested 
that PKCδ activation might be involved in the mode of action 
of HL-60 differentiations and apoptosis induced by ingenol and 
13-oxyingenol analogs, as reported previously.
42
 However, 13-
oxyingenol derivatives (1) and 13-oxyingenol 13-dodecanoate 
(70), each showing less potent PKCδ activation in vitro than 
PMA, significantly induced HL-60 cell differentiation and 
apoptosis (Table 3, Figures S3, S5, and S6), suggesting that 
these compounds induce activations of other PKC isozymes, 
although the possibility that migration of acyl groups in 1 and 
70 altered these compounds to be stronger PKC activators 
could not be excluded.
39b
 Therefore, the effects of broad-
spectrum PKC inhibitor Gö6983 on CD11b expression were 
examined. Interestingly, Gö6983 suppressed the up-
regulations of CD11b induced by 1 and 70 as well as other 
compounds (Figure S8). These results indicated that the 
activation of other PKC isozyme (or other kinases that Gö6983 
inhibits) might contribute to HL-60 cells differentiation induced 
by these 13-oxyingenols.
15c 
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Table 3 Biochemical and biological activities of 13-oxyingenol or ingenol analogsa 
 
 
 
 
 
 
Compounds R1 R2 R3 PKCα [%] PKCδ [%] CD11b [%] apoptosis [%] 
13-oxyingenols 
1 OCOC11H23 H COC5H11 19.9 (5.2) 14.2 (0.8) 152 (4.4) 40.8 (1.9) 
67 OH H H 16.9 (4.9) 11.5 (1.1) 13.6 (3.6) 6.7 (0.88) 
70 OCOC11H23 H H 17.0 (1.6) 11.8 (2.0) 170 (1.1) 35.6 (1.3) 
2 OCOC11H23 COCMe3 H 96.6 (4.1) 124 (1.4) 131 (2.3) 40.6 (1.5) 
76 OCOC11H23 COCMe=CHMe H 98.3 (8.8) 118 (7.9) 138 (4.4) 40.2 (2.2) 
77 OCOC11H23 COC13H27 H 69.7 (10.9) 82.2 (8.2) 162 (2.1) 37.4 (0.87) 
78 OCOC11H23 COPh H 88.3 (4.2) 109 (10.1) 130 (4.1) 41.3 (1.2) 
ingenols 
3 H H H 12.1 (3.1) 8.0 (2.3) 14.6 (3.0) 9.2 (0.80) 
84 H COCMe3 H 119 (3.7) 59.6 (5.8) 128 (2.7) 42.5 (0.85) 
4 H COCMe=CHMe H 98.0 (4.5) 37.6 (3.3) 141 (4.3) 41.2 (1.2) 
85 H COC13H27 H 88.3 (6.7) 103 (3.8) 130 (2.1) 43.4 (0.58) 
86 H COPh H 85.7 (12.0) 42.0 (7.0) 126 (2.0) 36.5 (1.2) 
PMA       100 100 100 43.7 (2.0) 
a PKCα and PKCδ; The increased activity by the treatment of the compounds (10 nM for PKCα; 100 nM for PKCδ) are presented as relative acitivity (% of control PMA); 
CD11b; Expression levels of CD11b induced by the compounds (1 μM, 24 h) in HL-60 cells are presented as the relative activity (% of control PMA); apoptosis; 
Apoptosis-inducing activity of the compounds (1 μM) for HL-60 cells was shown as population of sub G1 cells. 
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Fig. 3 Microscopic observations of HL-60 cells treated with 13-oxyingenol analogs. 
HL-60 cells were treated with PMA (1 μM) or 13-oxyingenol analogs (67 or 70, 1 
μM) for 24 h. 
 
Conclusions 
We have achieved the total synthesis of 13-oxyingenol 
derivative (1), featuring the RCM reaction for the construction 
of an inside–outside framework and Mislow–Evans-type [2,3]-
sigmatropic rearrangement for the stereoselective 
introduction of a hydroxy group at C5. The efficient 
functionalization of the A- and B-ring portions was established 
by using C2 and C7 hydroxy groups. Furthermore, we have 
investigated the structure–activity relationships  (SAR) of 13-
oxyingenol derivative (1) and ingenol (3). SAR studies of 
synthetic 13-oxyingenol analogs for PKCα and PKCδ activation 
reinforced the importance of esterification at the C3 hydroxyl 
group for PKC activation, and 2 and 76 proved to be the most 
powerful PKCδ activators. We also found that there are 13-
oxyingenol analogs having a long hydrophobic alkyl chain that 
induced HL-60 cell differentiation and cell death, though they 
were poorer PKCα and PKCδ activators than others or PMA. 
This showed the potential of 13-oxyingenol as a new scaffold 
for the development of therapeutic agents against acute 
myeloid leukemia. Various artificial analogs of 13-oxyingenol 
prepared by our synthetic strategy of 1 enabled us to obtain 
these new findings. 
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